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Abstract
Background: Adolescent-onset psychosis is associated with more severe symptoms and poorer outcomes than
adult-onset psychosis. The National Institute for Clinical Excellence (NICE) recommend that adolescents with first
episode psychosis (FEP) should be offered a combination of antipsychotic medication (APs), cognitive behavioural
therapy (CBT) and family intervention (FI). The evidence for APs in treating psychosis is limited in adolescents
compared to adults. Nevertheless, it indicates that APs can reduce overall symptoms in adolescents but may cause
more severe side effects, including cardiovascular and metabolic effects, than in adults. CBT and FI can improve
outcomes in adults, but there are no studies of psychological interventions (PI) in patients under 18 years old. Given
this limited evidence base, NICE made a specific research recommendation for determining the clinical and cost
effectiveness of APs versus PI versus both treatments for adolescent FEP.
Methods/design: The current study aimed to establish the feasibility and acceptability of conducting such a trial
by recruiting 14–18-year-olds with a first episode of psychosis into a feasibility prospective randomised open
blinded evaluation (PROBE) design, three-arm, randomised controlled trial of APs alone versus PI alone versus a
combination of both treatments. We aimed to recruit 90 participants from Early Intervention and Child and
Adolescent Mental Health Teams in seven UK sites. APs were prescribed by participants’ usual psychiatrists. PI
comprised standardised cognitive behavioural therapy and family intervention sessions.
Discussion: This is the first study to compare APs to PI in an adolescent population with FEP. Recruitment finished
on 31 October 2018. The study faced difficulties with recruitment across most sites due to factors including clinician
and service-user treatment preferences.
Trial registration: Current controlled trial with ISRCTN, ISRCTN80567433. Registered on 27 February 2017.
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Background
Psychosis is a mental health difficulty that encompasses a
range of experiences including unusual or distressing be-
liefs and/or hallucinations, cognitive difficulties and disor-
ganised speech and/or behaviour. In schizophrenia, a
specific psychotic disorder, positive symptoms such as hal-
lucinations and delusions can continue episodically for
years and people often experience persisting disability
partly due to negative symptoms (e.g. anhedonia and mo-
tivation loss) and cognitive difficulties (e.g. memory and
attention deficits) [1, 2]. Findings suggest that adolescent-
onset psychosis may be associated with more severe initial
symptoms than adult-onset [3] and a more severe course;
including greater functional impairment [4], poorer social
outcomes and educational achievement [5], more days in
hospital and greater readmission rates [6]. Adolescent-
onset psychosis and schizophrenia is associated with sig-
nificant societal costs and young people with psychosis
and schizophrenia accounted for 25% of adolescent psy-
chiatric inpatient admissions in England and Wales
between 1998 and 2004 [7]. Access to efficacious,
evidence-based interventions for young people with
psychosis is therefore vital. In this paper, we will use the
term “psychosis” to represent people both with and with-
out a diagnosis of a schizophrenia spectrum disorder. Em-
bracing diagnostic uncertainty is essential when working
with people with a first episode of psychosis (FEP), as pre-
mature diagnosis may lead to pessimism and consequently
poorer outcomes [8]; additionally, clients may perceive the
term “psychosis” as more acceptable than a diagnostic
label such as “schizophrenia” [8].
The National Institute for Health and Care Excellence
(NICE) guideline for psychosis and schizophrenia in
children and young people (CG155) recommends that
children and young people (CYP) should be offered oral
antipsychotic medication (APs) in conjunction with psy-
chological interventions (family intervention (FI) with
individual cognitive behavioural therapy (CBT)) [9]. If a
young person and their parents wish to try psychological
intervention alone, CG155 suggests that the care team
should advise that psychological interventions (PI) are
more effective when delivered in conjunction with APs,
but offer individual CBT and FI if the young person and
family wish to pursue that option [9]. However, CG155
also highlights that the evidence base available for these
treatments in CYP is limited and relies on evidence de-
rived largely from studies in adults.
A systematic review of pharmacological and psycho-
logical treatments for CYP with psychosis and schizo-
phrenia identified 19 studies of APs [10]. Meta-analysis
showed small effects of APs compared to placebo for
positive and negative symptoms, depression and psycho-
social functioning and large effects for global symptoms.
However, data quality across the studies was considered
poor [10]. A more recent meta-analysis of randomised
controlled trials (RCTs) confirmed the efficacy of APs in
CYP with psychosis but highlighted the limitations of the
evidence base, especially on safety outcomes [11]. Antipsy-
chotics are associated with a wide range of adverse effects
including cardiovascular, metabolic, hormonal and extra-
pyramidal adverse effects [12]. Compared to adults, CYP
may be more prone to developing antipsychotic adverse
effects [13]. In particular, antipsychotic-associated weight
gain is greater in FEP than in multi-episode schizophrenia
[14]. A study by Corell et al. [15] showed that 12 weeks of
antipsychotic treatment in children and adolescents, who
had less than 1 week’s prior antipsychotic exposure, was
associated with significant rates of obesity and new-onset
categorical glucose and lipid abnormalities. For example,
weight gain > 7% in the participants ranged from 56%
(when participants were treated with quetiapine) to 84%
(with olanzapine) [15]. To date, there are no studies evalu-
ating the long-term safety of APs in adolescents with
psychosis. Therefore, evaluating long-term cost-benefit ra-
tios is not currently possible. For some adolescents with
psychosis, the risks of APs may outweigh their benefits.
Moreover, discontinuation of APs against medical advice
and non-adherence are common in schizophrenia, espe-
cially in the first episode [16]. Together, these factors
support the importance of assessing potential non-
pharmacological treatment options for psychosis.
There are currently no trials of CBT or FI with CYP
under 18 years old with psychosis [10]. There are seven
low-quality studies of CBT and/or FI for psychosis in
young people (aged between 15 and 24 years old). Meta-
analysis of the data from these studies indicates no
evidence of treatment effects on symptoms, and low-
quality evidence for a combination of CBT and FI on the
number of days to relapse [10]. There is better-quality
evidence for the effectiveness of psychological interven-
tions for psychosis from studies conducted in adults.
Meta-analyses in adult populations suggest that a com-
bination of CBT and APs has small but statistically sig-
nificant effects on symptoms and rehospitalisation rates
[17, 18]. FI has been shown to reduce relapse rates [19],
and there is a signal that CBT alone can reduce symp-
toms in adults who choose not to take APs, particularly
in participants under 21 years old [20]. The COMPARE
trial [21], which allocated people aged 16+ years with
FEP to receive either APs, CBT or a combination of
both, found no differences in Positive And Negative Syn-
drome Scale (PANSS) scores between the AP-only and
the CBT-only group, or between the combination group
and the AP-only group at 12-months. However, PANSS
scores were significantly lower in the combination group
than in the CBT-only group at 12 months. Those in the
CBT-only group reported fewer non-neurological side
effects than those in the AP-only and combined groups
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[21], suggesting a potential for reduced adverse effects.
A fifth of participants on the COMPARE trial (15 out of
75) were aged 16–18 years.
In summary, the NICE guideline (CG155) group deter-
mined that the available evidence, including that from
adults, was sufficiently strong to recommend a combin-
ation of APs, CBT and FI as treatments for CYP with
psychosis. However, for CYP with psychosis the balance
of risks and benefits of APs appears less favourable and
research is needed to establish the potential for psycho-
logical treatments, alone and in combination with APs,
in this population. Consequently, CG155 recommended
research to determine the clinical and cost effectiveness
of psychological treatment alone, compared with anti-
psychotic medication and compared with psychological
treatment and antipsychotic medication combined [9].
Subsequently, the National Institute for Health Research
(NIHR), Health Technology Assessment Programme
(HTA) put out a commissioned call (HTA 51/13) to an-
swer this research question.
The Managing Adolescent first episode Psychosis
Study (MAPS) is funded by the UK NIHR HTA
programme to establish whether it is feasible and accept-
able to run a definitive trial examining the effectiveness
of antipsychotic monotherapy versus psychological inter-
vention (CBT plus FI) versus a combination of these
treatment options in adolescents with FEP. This will an-
swer important questions about the feasibility and design
of a definitive clinical and cost effectiveness trial as rec-
ommended by NICE guideline CG155.
Methods/design
Our specific objectives were to assess (1) the proportion
of eligible people that clinicians are willing to refer to the
trial, and the proportions of eligible referred people that
are willing to participate and to comply with their alloca-
tion; (2) the rates of adherence to follow-up assessments;
(3) the characteristics of trial participants (to clarify selec-
tion criteria); (4) the feasibility and acceptability of the
interventions to participants, parents and clinicians, and
the appropriateness of treatment protocols; (5) the ran-
domisation and masking procedures and (6) the validity
and relevance of the measures to determine their accept-
ability, effectiveness and safety in a definitive trial. Further-
more, we aimed to estimate plausible ranges of sample
size parameters to inform a definitive trial; finalise treat-
ment manuals and outcome measures, and clarify train-
ing/supervision needs for delivering assessments and
interventions; and assess the possibility for economies of
scale, and monitor the research assistants’ time use.
This study is a prospective randomised open blinded
evaluation (PROBE) design, feasibility, RCT, which aimed
to recruit 90 participants with FEP. As a PROBE study,
persons (research assistants) that were unaware of the
randomisation allocation made decisions about the scor-
ing of outcome measures. We did not have a blinded end-
point committee, however, our independent Data Moni-
toring and Ethics Committee (iDMC) provided oversight
of unblinding.
The randomisation ratio was 1:1:1, stratified by centre
and family contact (as participants without regular family
contact only received individual CBT and not FI, if rando-
mised to the PI-only and combined groups). Randomisa-
tion at the individual level was independent and
concealed, using random permuted blocks. Research assis-
tants (RAs) performed the randomisation procedure via a
study-specific website developed by the Centre for Health-
care Randomised Trials (CHaRT), the UK Clinical Re-
search Collaboration (UKCRC) registered Clinical Trials
Unit (CTU #7) supporting the study. Aside from the trial
therapists, the Trial Manager and Chief and Principal In-
vestigators received emails informing them of randomised
treatment allocation, so they could monitor adherence to
allocation and provide supervision to therapists. The trial
administrator was also informed via the same methods,
and sent letters to participants to inform them of their al-
location. Participants’ care teams, including their treating
psychiatrist, were also informed of allocation.
Trial RAs were blind to the participants’ allocations until
all outcome measures were completed for all participants.
Maintaining the outcome assessor blind is crucial for ef-
fectiveness outcomes and also throughout the trial for
measuring safety. The iDMC and Trial Steering committee
(TSC) regularly monitored unblinding by each centre, and
were able to implement corrective action if necessary. RAs
and therapists received rigorous in-house training on the
importance of maintaining the blind and methods to
achieve this, and were required to read and sign our stand-
ard operating procedure (SOP) for retaining and managing
blinding. Methods outlined in the SOP included separate
offices for the therapists and RAs, protocols for answering
telephones, including reminders for clinicians, participants
and family members about the blind, protocols for message
taking and secretarial support, separate diaries, pigeon
holes and databases, using passwords and encryption of
randomisation information. Any accidental unblinding was
recorded. The Chief Investigator (CI) reviewed all unblind-
ing to determine any patterns.
We recruited participants from Early Intervention in
Psychosis (EIP) teams and Child and Adolescent Mental
Health Services (CAMHS) in UK National Health Ser-
vice (NHS) Trusts across seven sites; Greater Manches-
ter, Lancashire, Oxfordshire and Buckinghamshire,
Sussex, Northumberland, Tyne and Wear, Norfolk &
Suffolk, and Birmingham. We included 14–18-year-olds
presenting with FEP who were under the care of EIP
and/or CAMHS services and who were seeking help for
their experiences. Participants had to be within a year of
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presentation to services with psychosis and score 4+ on
the PANSS delusions and/or hallucinations subscale(s)
for a minimum of seven consecutive days, to determine
their first-episode status and current symptomology.
They also needed to either meet International Classifica-
tion of Diseases Version 10 (ICD-10) criteria for schizo-
phrenia, schizoaffective disorder or delusional disorder
(according to the diagnosis recorded by the treating
psychiatrist) or entry criteria for an EIP service. Finally,
participants had to be competent to provide written, in-
formed consent and those under 16 years old had to
have a parent/guardian willing to provide additional con-
sent to contact their child (for ethical reasons). If allo-
cated to a PI arm, participants chose whether they
wished to engage in FI. If participants did not wish to
engage in FI, they were not prevented from participating
in the trial and receiving CBT. No research procedures
were carried out with family members, i.e. we did not
collect any data on them or from them.
We excluded people who had diagnoses of a moder-
ate/severe learning disability, ICD-10 organic psychosis,
or primary alcohol/substance dependence (to ensure that
our population was representative of young people with
a primary problem of FEP), those who could not speak
English, who scored 5+ on the conceptual disorganisa-
tion item of the PANSS (to ensure that people had cap-
acity to engage in assessments and talking therapy),
those who presented with immediate risk to themselves
or others, or who had received APs or structured PI
within the last 3 months prior to referral (to ensure
treatment naivety). We did not exclude those with autis-
tic spectrum disorder (ASD).
The protocol is reported in adherence with the Stand-
ard protocol items: recommendations for interventional
trials (SPIRIT) guidelines; see Additional file 1.
Interventions
Psychological intervention
PI was delivered by appropriately trained therapists (clinical
psychologists or other mental health professionals with
relevant training in CBT for psychosis (CBTp)). Participants
were offered up to 30 sessions of individual CBT over a 6-
month treatment window on an approximately weekly
basis, and the option of up to six sessions of FI. Both CBT
and FI were informed by an integrative cognitive model of
psychosis [22]. This therapeutic model has been used suc-
cessfully in other clinical trials in young people with psych-
osis, and participants within these studies provided positive
qualitative interview feedback about its acceptability and
usefulness [23]. Therapists took an assertive outreach ap-
proach developed from youth work principles and adopted
principles from social and vocational interventions (e.g.,
supported education and/or employment interventions).
The overall aims of CBT were to reduce distress (particu-
larly that arising from psychotic symptoms) and improve
quality of life. CBT involved assessment and psychological
formulation of people’s problems and goals, to allow an
individualised therapeutic approach whilst retaining stan-
dardised components and clear boundaries. CBT was col-
laborative, with therapist and client agreeing on problems
and goals to work on, using interventions dependent on cli-
ents’ individualised formulations from a range described in
our published manuals [24–26]. There were a range of
treatment targets including positive symptoms, comorbid
problems (including anxiety, depression and substance use)
and social issues such as improving relationships, develop-
ing valued social roles and maintaining functioning.
There were 4 phases to the CBT intervention: (1) en-
gagement, assessment and formulation of problems and
goals; (2) formulation-derived change strategies enabling
people to work towards their individual goals; (3) develop-
ment of an historical formulation, focusing on vulnerabil-
ity factors leading to the development of FEP and
including self-esteem work and (4) maintaining wellness
and preventing relapse.
FI was grounded in a psycho-educational model of fam-
ily work based on the behavioural family therapy (BFT)
approach [27]. An initial session included an assessment
of family understanding and appraisals of presenting diffi-
culties, sharing the emerging psychological formulation,
and agreeing a problem list and family intervention goals.
Further sessions included an educational component to
develop a common understanding, providing normalising
and recovery-orientated information on presenting diffi-
culties, problem-solving, communication skills training
and relapse prevention planning. Families were given
between-session tasks and encouraged to hold family
meetings to support skills practice. Family members were
also given information about local services and signposted
to support for themselves, where appropriate. The ap-
proach was flexible and multi-faceted in response to needs
and concerns addressing specific issues relating to
adolescent-onset psychosis, including diagnostic uncer-
tainty; dealing with emotional reactions/feelings evoked by
the onset of psychosis; helping families “grieve” while en-
couraging a sense of agency and hope for recovery. FI was
delivered in tandem with individual CBT by the same
therapist. A maximum of six FI sessions were offered,
spread out across the 6-month therapy window to match
the pacing and content of individual CBT sessions and re-
spond flexibly to concerns of family members as they
arose. The final session was offered in collaboration with
the participant’s care co-ordinator to ensure continuity
following trial involvement and ensure goals/strategies are
shared and supported.
To ensure fidelity to the treatment protocol, therapists
received initial training and weekly supervision. With
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consent, therapy sessions were audio-recorded, and a
randomly selected sample of tapes (stratified by stage of
therapy) rated using the Cognitive Therapy Scale – Re-
vised (CTS-R) [28]. The tape rating process continued
throughout the lifetime of the trial to guide supervision,
ensure fidelity to the treatment protocol and enable cor-
rective action to be taken if necessary. Therapists com-
pleted session records after each appointment to provide
detail about session content (e.g., agenda items, change
strategies used and homework tasks).
Antipsychotic medication
Participants allocated to receive APs in the monotherapy
or combined arms of the trial received their prescrip-
tions from their usual psychiatrist in their care team.
The psychiatrist was asked to make prescribing decisions
consistent with the NICE guideline CG155, which rec-
ommends that clinicians should jointly decide the choice
of antipsychotic medication with the young person and
their parents/carers. The decision about medication
should include discussion about the possible benefits
and side effects of each drug, and provision of age-
appropriate information [9]. AP prescribing should also
be accompanied by physical health monitoring [9].
Psychiatrists were encouraged to initiate AP treatment
as soon as possible following randomisation into the
study, and to maintain AP treatment preferably for 26
weeks, but for 12 weeks minimum. The decision about
the type and dose of AP was made by the psychiatrist as
per their usual practice, i.e. we did not ask them to
choose from a pre-specified list of antipsychotic medica-
tions. Psychiatrists were free to change dose and type of
AP in response to efficacy and adverse events. A mem-
ber of the research team who was not blind to allocation
screened participants’ medical records to collect details
about AP prescription. Additionally, self-report data
were provided by participants either via our web-based
platform or if preferred, in paper format that was
returned to a research team member who was not blind
to allocation. Psychiatrists on the study were available
for consultation if participants’ CAMHS or EIP psychia-
trists wished to discuss AP prescription.
We did not restrict the treatment options offered by
the care team as it would have been unethical to do so.
Additionally, participants were eligible to receive mental
health medications other than APs, and psychological
therapies other than and including CBTp or FI, through-
out the course of the trial. A member of the research
team who was not blind to allocation screened partici-
pants’ medical records for information on concomitant
therapies received. In addition, self-report data on con-
comitant therapies were provided by participants using
the method described above. Data from participants’
medical records and self-report data provided important
feasibility information about participants’ adherence to
their randomised treatment allocation.
Outcomes
We do not have a single primary outcome, as this is not
meaningful for a feasibility study. Our key outcomes to in-
form a definitive trial are rates of referral, recruitment,
therapy attendance, adherence to medication, and comple-
tion of follow-up appointments and questionnaires. The
acceptability of treatment will be determined by measur-
ing discontinuation rates and through data collected
within a nested qualitative study (see below). We have
specific red/amber/green progression criteria that have
been agreed with our iDMC, TSC and funder. Green
would mean progression to a full trial is possible without
the need for any substantial changes to the design or the
way it was delivered; amber would mean we may need
more resource to recruit, and ways of improving retention
and compliance; and red would mean there is substantial
doubt that the definitive study is feasible at an affordable
cost. These progression criteria will be reviewed by the
iDMC and TSC at the end of the trial and will inform a
recommendation for a definitive trial. The progression cri-
teria to a future definitive trial are described below:
1. Recruitment ≥ 80% of planned (green), recruitment
within 79–60% of planned (amber), recruitment
< 60% of planned (red).
2. Retention of participants within the study with
baseline and outcome assessments at primary end
point (6 months, end of treatment) ≥ 80% of primary
outcome completed (green), 79–60% of primary
outcome completed (amber), < 60% of primary
outcome completed (red).
3. Satisfactory delivery of adherent therapy to ≥ 80%
of groups receiving PI (green), 79–60% of groups
receiving PI (amber), < 60% of groups receiving
PI (red). Satisfactory delivery of adherent therapy
is operationalised as attending 6 or more sessions
of CBT.
4. Satisfactory delivery of antipsychotic medication to
≥ 80% of groups receiving AP (green), 79–60% of
groups receiving AP (amber), < 60% of groups
receiving AP (red). Satisfactory delivery of
antipsychotic medication is operationalised as any
exposure of AP for six consecutive weeks (this would
include a dose below British National Formulary
(BNF) lower limits given this is a frequent clinical
practice for people of this age, and APs are licensed
for adults).
We have a number of secondary outcomes, which
were collected from participants via self-report and
interview measures at baseline and follow-up
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appointments (see Fig. 1 for schedule of enrolment, in-
terventions and assessments). This is to assess the ac-
ceptability and usefulness of the measures for inclusion
in a definitive trial, rather than to measure the relative
safety/efficacy of the interventions. Our provisional
choice of primary outcome measure for a definitive trial
is total PANSS score, which would ensure comparability
to other antipsychotic and psychological therapy trials;
however, a final decision on a primary outcome will need
to be informed by data from this trial, associated qualita-
tive studies and stakeholder opinion. The PANSS is a
30-item rating scale for psychopathologic assessment of
adults with a diagnosis of schizophrenia [29]. It is a fre-
quently used outcome measure in psychosis research.
We assessed social and educational/occupational func-
tioning with the First Episode Social Functioning Scale
(FESFS) [30], a questionnaire developed with people pre-
senting with FEP that has good reliability, validity and
sensitivity to change. We measured subjective recovery
using the 15-item version of the Questionnaire about
the Process of Recovery (QPR) [31], a questionnaire de-
veloped in collaboration with people with psychosis. We
used the Specific Psychotic Experiences Questionnaire
(SPEQ) [32] to assess paranoia, hallucinations, cognitive
disorganisation, grandiosity and anhedonia.
To measure common comorbidities, we used (1) the
Hospital Anxiety and Depression Scale (HADS) [33],
which has shown to be reliable and valid in measuring
anxiety and depression symptoms over the past 7 days;
(2) the Alcohol Use Disorder Identification Test
(AUDIT) [34] and (3) the Drug Abuse Screening Test
(DAST) [35]. The latter two measures are statistically
predictive of the respective substance misuse disorders,
using the Structured Clinical Interview for the Diagnos-
tic and Statistical Manual version 5 (DSM-IV) (SCID-
IV) [36]. We also measured diagnostic symptoms for
autism spectrum conditions at baseline using the NICE-
recommended 10-item version of the Autism Spectrum
Quotient (AQ-10) [37]. We collected data on adverse ef-
fects of medication and trial participation (described
Fig. 1 Schedule of enrolment, interventions and assessments. APs, antipsychotic medication; ANNSERS, Antipsychotic Non-Neurological Side Effects Scale;
AQ-10, Autism Spectrum Quotient 10-item version; DAST, Drug Abuse Screener Test; DUP, duration of untreated psychosis; EPQ, Economic Patient
Questionnaire; EQ-5D, EuroQol five dimension scale; FESFS, First Episode Social Functioning Scale; HADS, Hospital Anxiety and Depression Scale; PANSS,
Positive And Negative Syndromes Scale; PI, psychological intervention; QPR, Questionnaire about the Process of Recovery; 3MFU, 6MFU, 12MFU 3-month,
6-month, 12-month follow up. *Only for participants who were randomised after the first 10 months of the trial and thus were not offered a 12MFU
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further under “Safety Monitoring”). We collected basic
health economics data about services used by partici-
pants, using an economic patient questionnaire adapted
from previous studies conducted by the authors [38, 39]
and the EuroQol five dimension, five level scale (EQ-5D-
5 L) health status questionnaire [40]. This information
will inform the design of the economic component of a
definitive trial.
We designed a variable-length follow-up period,
whereby participants recruited in the first 10 months
were offered assessments at 3, 6 and 12 months and
those recruited thereafter were only offered assessments
up to the end of treatment (6 months, the proposed tim-
ing for the primary outcome). RAs collected all outcome
measures at baseline and at the 3-month, 6-month and
12-month follow-up assessments. RAs underwent in-
house training in administering all the measures to
establish sufficient inter-rater reliability, including
watching and scoring role-play and videos. These train-
ing sessions occurred prior to RAs delivering assess-
ments independently and on several occasions
throughout the course of the trial, to prevent “rater
drift”. Measures were administered in a specific order
agreed by the trial manager and CI to prioritise the most
important (beginning with the PANSS).
To promote retention to the trial and reduce participant
burden, RAs worked in a person-centred manner and gave
participants control where possible over the location and
time of appointments, offered breaks and multiple visits to
complete measures, and gave the option of skipping mea-
sures if participants found them difficult to complete. Par-
ticipants were compensated £10 per assessment and RAs
contacted participants between follow-up appointments
with a “check-in” phone call and a £5 shopping voucher.
These processes are consistent with systematic review evi-
dence for increasing retention in clinical trials [41]. RAs re-
ceived weekly trial management supervision to enable
monitoring of follow-up rate retention and to proactively
problem-solve issues with completing assessments.
Safety monitoring and reporting
We took a rigorous approach to recording and reporting
serious adverse events. We recorded all serious adverse
events (SAEs) at each point of contact with participants
after randomisation. Our definition of an SAE was in-
formed by the standard Health Research Authority def-
inition and our trial protocol, which included all deaths,
life-threatening incidents including suicide attempts,
serious violent incidents, hospital admissions including
admissions to secure units (we record whether these are
voluntary or involuntary) and physical health units, pro-
longation of hospitalisation, any events resulting in per-
sistent or significant disability or incapacity, any event
consisting of a congenital abnormality or birth defect
and formal complaints about treatment.
As noted, we scrutinised any instances of participants
being admitted to psychiatric hospitals throughout the
trial. The therapists or RAs were likely to have become
aware of adverse events or admissions to psychiatric hos-
pitals; however, we also screened each participant’s med-
ical notes to assess for adverse events. All SAEs were
monitored by the iDMC and TSC. All related and unex-
pected SAEs were reported to the National Research Eth-
ics Committee (NREC) and the participant’s NHS Trust.
We measured potential adverse effects associated with
trial participation at the participant’s final follow-up as-
sessment (i.e. 6 months or 12months, dependent on when
they were randomised into the trial), using a measure de-
veloped in our HTA-funded FOCUS trial [42]. In addition,
if a participant in the monotherapy arm experienced a
substantial deterioration in their mental health throughout
the study, they were offered a switch to the combined
treatment arm. This would be offered if the participant’s
mental state had significantly deteriorated from baseline
at the 3-month follow-up appointment (operationalised by
an increase of 12.5% or more in rescaled PANSS scores)
or if they were admitted involuntarily to hospital at any
point in the trial.
We measured adverse effects of medication; firstly by
interviewing participants using the Antipsychotic Non-
Neurological Side Effects Scale (ANNSERS) [43], and
secondly by measuring weight, height, waist circumfer-
ence and blood pressure. In addition, a blood sample
was taken for assessment of fasting plasma glucose
(FPG), glycated haemoglobin (HbA1C), serum prolactin
levels, and lipids (total cholesterol, low-density lipopro-
teins (LDL), high-density lipoproteins (HDL) and triglyc-
erides). ANNSERS, physical examinations and blood
tests were conducted at baseline and at the 3-month, 6-
month and 12-month assessment. The results of blood
tests were sent to participants’ psychiatrists (or other re-
sponsible clinician) at each time point. Finally, during
screening of participants’ medical records for SAEs as
described above, we recorded any adverse events related
to antipsychotic medication (i.e., side effects) that were
reported in participants’ notes.
Consent
RAs were responsible for consenting participants into
the trial under the supervision of the Chief and Principal
Investigators. In addition to receiving Good Clinical
Practice training, RAs completed the online module “In-
formed Consent in Paediatric Research” offered by the
NIHR. Parents/legal guardians and potential participants
had at least 24 h to read the Research Ethics Committee
(REC)-approved participant information sheet, before
meeting with an RA for the informed consent visit. If
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the young person was under 16 years old, RAs were re-
quired to obtain written informed consent from their
parent/legal guardian to contact the young person prior
to taking written informed consent to participate from
the young person. The RAs followed the same procedure
as above to ensure parents/guardians were fully in-
formed and understood the study information, and if
satisfied, the RA requested the parent to sign an assent
form allowing the RA to contact their child about the
study. The RA could then arrange to meet with the
young person to sign their own consent form. Ongoing
consent was confirmed at each research assessment and
documented in the participant’s research notes.
Trial oversight
The Sponsor of the trial is Greater Manchester Mental
Health NHS Foundation Trust. The Sponsor was respon-
sible for auditing the conduct of the trial. Independent
oversight of the trial was provided by the iDMC and TSC.
The iDMC was composed of an independent chairperson,
statistician, clinician and service user. The role of the iDMC
was to monitor recruitment of study participants, ethical is-
sues of consent, quality of data (including missing data), the
incidence of adverse events, unblinding and withdrawals
and any other factors that might have compromised the
progress and satisfactory completion of the trial. The iDMC
met on a 6-monthly basis. A copy of the iDMC charter was
retained by the Trial Manager in the site file.
The TSC was composed of an independent chairperson,
statistician, clinician and service user along with non-
independent members; the CI, trial manager, a representa-
tive of the funder (NIHR HTA) and a representative of the
Sponsor. The TSC met every 6months to monitor and
supervise progress, and consider reports and recommen-
dations. Meetings occurred approximately 2–4 weeks after
the iDMC so the iDMC report could inform the TSC
meeting. Prior to each iDMC and TSC meeting, the inde-
pendent members were required to declare any conflicts
of interest. The outcome of each iDMC and TSC meeting
was reported to the funder via the minutes of the meeting.
The trial management group, which comprised grant ap-
plicants and other local investigators met on an approxi-
mately monthly basis to provide management oversight of
recruitment, attrition, adverse events, blind breaks, with-
drawals and data management. Following the addition of
three more sites in May and June 2018, individual site
management meetings were organised on a monthly basis
to ensure oversight of site-specific issues.
Data management
All of the information collected about the participants is
strictly confidential. All participants’ personal identifiable
data (PID) are kept securely in databases, on secure NHS
computer drives that are only accessible to the research
team and are protected by a password known only by study
staff. All RAs’ computers are also individually password-
protected. Paper copies of research data (i.e. assessment
packs) are anonymised with a trial identification (ID) num-
ber and kept in a locked, filing cabinet separate to the stor-
age of PID (such as referral forms and letters about the
participant). Participants were made aware that although
their data are strictly confidential and not shared outside of
the research team, confidentiality could be broken in cases
where participants were deemed to pose a risk to them-
selves or to others.
All research data entered on the secure web-based
platform created by CHaRT were completely anon-
ymised. To ensure the accuracy of the data entry for the
proposed primary outcome measure (PANSS), RAs
checked entries for every participant by comparing
PANSS scores in the paper assessment files against the
scores entered into the CHaRT platform. Data were
checked once all possible assessments for each time
point were completed. An error rate of 2% or less was
deemed acceptable. If the error rate had been above 2%
the trial statistician and methodologist would have ad-
vised on further data checking, although this was not ne-
cessary due to the accuracy of the data entry.
The final trial dataset is managed and held by our CTU,
CHaRT. Requests for access to the dataset will be consid-
ered in the first instance by the CI and then the CTU.
Sample size
We proposed a sample size of 90 participants across all
sites (30 per treatment arm). The target sample size is
sufficient to attain reliable sample size estimates [44],
gain feasibility information about trial proceures and fa-
cilitate a power calucalation. No power calculation was
performed for this study as the focus of feasibility study
analysis is not hypothesis testing [45]. We will estimate
95% confidence intervals to indicate likely intervention
effects for a definitive trial.
Recruitment
We had a team of highly motivated research staff who
were experienced in recruiting participants into clinical
trials, working across carefully selected NHS sites with
which we have successfully collaborated on previous tri-
als. Many of our sites had established relationships with
EIP and CAMHS teams due to having research staff em-
bedded within the teams, and/or due to recruitment
efforts in previous trials. All sites covered extensive geo-
graphical areas. We used a joint-working approach be-
tween research and clinical teams in each site to build
positive relationships with clinical staff, identify all po-
tential cases and encourage clinical staff to discuss the
trial with service users to enhance the referral rate. This
included regular contact between the RAs and the
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clinical teams. Supervision and team meetings allowed
RAs to provide feedback on teams they were struggling
to contact so that the team could collectively problem-
solve ways of moving forward.
To ensure fidelity to the allocated treatment, we
endeavoured to work closely with EIP and CAMHS psy-
chiatrists. The exclusion criterion of AP treatment naiv-
ety meant that engaging those who prescribe to CYP
with psychosis was an important aspect to recruitment.
The trial design required the participant’s usual psych-
iatrist (within their care team) to prescribe an AP as
soon as possible after randomisation, if the participant
was allocated to the AP monotherapy or combined treat-
ment arms. To engage EIP and CAMHS psychiatrists we
ran continuing professional development (CPD)/training
events, and the CI directly contacted psychiatrists to ask
for their support. Additionally, NIHR-funded clinical
studies officers (CSOs) within many sites had existing
relationships with teams and helped promote the study,
identified research-motivated staff and where possible
reviewed team caseloads for potential MAPS candidates.
MAPS began recruiting in April 2017 as a four-site
trial with a 15-month recruitment window (projecting
1.5 randomisations per month per site). The actual ver-
sus target site-recruitment varied considerably between
sites. Barriers to recruitment were identified across all
sites. In some instances, there was a strong treatment
preference expressed by clinicians, young people and/or
parents, which influenced referral to the trial and/or
young people agreeing to take part. The incidence rates
of young people either being referred to, or accepted
into EIP teams were relatively low across all sites, al-
though numbers did vary by site. We also found vari-
ation in the inclusion/exclusion criteria of EIP services
both across and within sites, particularly in terms of ap-
plying diagnostic uncertainty to people’s experiences.
For example, some teams did not accept people whose
psychotic experiences were judged a product of mood,
trauma or personality-related difficulties, or where the
duration of untreated psychosis reached a particular
threshold. As a result, in some instances this led to a
discrepancy between young people’s eligibility for MAPS
and for an EIP service. As AP prescription was made by
the participant’s usual psychiatrist, entry into the trial
was dependent on the young person’s psychiatrist agree-
ing that randomisation to either or both MAPS treat-
ments would be appropriate. The discrepancy between
MAPS inclusion criteria and individual EIP inclusion cri-
teria therefore further limited the already small number
of young people who were potentially eligible for the
trial. Additionally, due to the necessity of psychiatrists
agreeing to young people entering the trial (including
not prescribing APs for them prior to trial entry as de-
scribed above), engaging psychiatrists with positive views
of the trial embedded within EIP/CAMHS teams was
crucial for recruitment. This was not possible across all
services due to clinicians’ individual views and practices in
relation to the treatment of FEP in young people. Another
factor that proved challenging to recruitment was the rela-
tively large proportion of young people who had already
been prescribed APs prior to initial contact with EIP/
CAMHS services (for example, via care pathways involv-
ing crisis/home treatment teams or inpatient services).
The most successfully recruiting MAPS site engaged
psychiatrists embedded within EIP who regularly con-
ducted service assessments, and could therefore provide
an opinion on whether there was clinical equipoise for a
young person early into their accessing services (before
prescription of APs is made). In order to evaluate the
feasibility of replicating this model approach to recruit-
ment we added three new sites (Birmingham, Norfolk &
Suffolk and Northumberland, Tyne and Wear) in May
2018, and extended our recruitment window by four
months to 31 October 2018.
Data analysis
The main aims of the feasibility trial will be delivered
both via the continued monitoring of descriptive data
and the analysis of data following the last follow-up as-
sessment. Analysis is ongoing and began after full re-
cruitment and follow up (i.e. there were no interim
analyses for efficacy, although the iDMC monitored trial
progress and any safety issues on a regular basis).
The main analyses are based on an intention-to-treat
approach, using all randomised participants. Since safety
and unwanted effects should be analysed on the basis of
the most accurate information, these analyses are based
on treatment received rather than as-randomised. Treat-
ment received for the analysis of safety and unwanted ef-
fects is defined as any dose of an antipsychotic prescribed
by the participant’s responsible psychiatrist and any dose
of CBTp or FI from a trial therapist. We will use descrip-
tive statistics to summarise the key indicators of success
of the trial, including participant recruitment; checks for
absence of selective recruitment of participants; baseline
balance and participant flow. We will report data in line
with the consolidated standards of reporting trials (CON-
SORT) 2010 extension statement for pilot and feasibility
trials [46]. Important summary statistics will be the num-
ber of participants referred through case managers and
mental health staff, number of referrals found to be eli-
gible and number of consenting individuals and recruited
individuals to each arm. Numbers for discontinuation
from the allocated interventions, withdrawal of consent
and failure to provide follow-up outcome data will also be
generated. We will also report the proportion of partici-
pants who received their allocated intervention compared
to the proportion who did not, and the proportion of
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participants offered a move to the combined therapy arm
due to deterioration.
We will report our feasibility results (recruitment, reten-
tion, adherence) overall, in order to inform decisions
about the viability of a future definitive trial. However, we
will also report our descriptive results and 95% confidence
intervals on outcome measures by group. We will describe
actual treatment received and treatment compliance (to
account for departures from the randomised interven-
tions). We will also report descriptive statistics for the
components of psychological intervention received, in-
cluding number of sessions and milestones achieved.
To inform a phase III trial we will conduct the follow-
ing analysis to ensure the data conform to the assump-
tions of the tests that will be conducted at that stage:
measures proposed as the primary (PANSS) and second-
ary outcomes (QPR) for the phase III study will be ana-
lysed by analysis of repeated measures using a mixed
effects model to account for the discrete timing of the
follow-up assessments. The presentation of the analysis
will focus on point estimates and associated 95% confi-
dence intervals rather than statistical significance (p
values). Further analysis will test the correlation of each
measure across all time points and the variation within
the proposed outcome measure (mean and standard de-
viation) to inform a definitive sample size calculation for
a phase III trial. No formal analysis will be performed to
account for missing data as MAPS is a feasibility study.
We will measure within trial and also explore the lit-
erature on the possible effects of clustering by therapist
and site. We anticipate that the chance of clustering in
relation to drug outcomes will be negligible, given that
we are expecting prescribing to follow NICE (CG155)
guidance, although we will measure this in case of sig-
nificant differences in prescribing practices between
sites. We will adjust for site in analyses (therapist will be
nested within site) and examine intraclass correlation
coefficients to inform a plan for managing any such im-
pact on design and analysis of a definitive trial.
All statistical analyses are pre-specified in a compre-
hensive statistical analysis plan (SAP) authored by the
study statistician and agreed with the iDMC and TSC.
Intervention and trial acceptability: qualitative interviews
A nested qualitative study aimed to identify key themes
associated with the acceptability of the trial and inter-
ventions amongst CYP, family members/carers and clini-
cians. Individual semi-structured interviews explored
participants’ subjective experiences of recruitment, ran-
dom allocation and receiving interventions, including
views of adverse effects and benefits; sought to identify
barriers and solutions to participation; and ultimately
aimed to identify themes relating to all of these issues.
This will inform the design of a definitive trial and help
further refine intervention, recruitment and retention
procedures. We sought a maximum variance sample on
key variables among participants (gender, age, ethnicity,
site, engagement with interventions). The CYP inter-
views were conducted with participants from all treat-
ment arms within the trial after 6 month assessments;
this allowed us to explore people’s experiences of receiv-
ing the treatments and of participating in the trial. Based
on our previous work we expected thematic saturation
would be achieved within 15–20 CYP interviews [47],
15–20 family members/carers [48] and 15–20 clinicians.
All interviews were audio-recorded and transcribed ver-
batim at which point any identifying information (names
and places) was removed. Data are currently being the-
matically analysed [49]. This method results in a rich
and accessible account of qualitative data through the
researcher making sense of the data and reporting
themes that emerge [49]. Data were coded systematically
and iteratively, and were organised within Nvivo qualita-
tive data analysis Software version 11 [50].
Dissemination
The results from this study will be published in a peer-
reviewed journal for dissemination amongst researchers
and clinicians. We will follow the International Commit-
tee of Medical Journal Editors (ICMJE) recommenda-
tions for authorship and review these for each individual
publication. The results will also be disseminated to par-
ticipants, if they agree to this. Participants leaving the
trial were asked whether they would like the results of
the study and their preferred method for receiving them
(e.g. post, telephone, email). The results will also be dis-
seminated amongst the healthcare professionals and
teams that have helped support recruitment for the trial.
Discussion
Our trial is the first of its kind, as we are not aware of
any other feasibility trials that have recruited young
people with FEP into a three-arm RCT of AP monother-
apy, PI monotherapy or a combined treatment. Our trial
has a number of strengths including using methods to
minimise selection bias, such as generation of rando-
mised permuted blocks via a computer system and cen-
tralisation of allocation via a web-based platform. We
adhered to detailed operational procedures to minimise
detection bias as outlined in our SOP for maintaining
the blind. We have a low risk of selective reporting as
we have published our SAP on the CTU website follow-
ing agreement by our iDMC and TSC. We used a rigor-
ous approach to recording and reporting SAEs,
including reports from trial staff and medical record
screening for details of SAEs, as specified in our iDMC-
approved SOP for SAEs. Moreover, we go beyond UK
Health Research Authority (HRA) requirements for
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review of SAEs and in addition to review by the CI, the
iDMC chairperson provided an independent review of
whether each SAE is trial-related or not. In addition, our
trial included a bespoke measure of potentially un-
wanted effects of trial participation.
In summary, APs and psychological interventions (PI),
specifically, family intervention and cognitive behaviour
therapy are recommended treatments for FEP in adoles-
cents but evidence about relative efficacy/acceptability is
limited. If PI were non-inferior to APs, within an accept-
able margin, this could be a major advance in treating a
vulnerable group with high sensitivity to APs. The
MAPS trial provides crucial data on the feasibility and
acceptability of conducting a phase III trial of these
treatments and the conditions that would be required to
conduct such a trial.
Trial status
Recruitment began on 1 April 2017 and ended on 31 Oc-
tober 2018 with a total of 61 participants randomised into
the trial across six of the seven sites: 25 in Oxfordshire
and Buckinghamshire, 21 in Greater Manchester, 9 in
Lancashire, 4 in Sussex, 1 in Northumberland, Tyne and
Wear and 1 in Birmingham. This represents 67.8% of the
original target of 90 participants. All PI sessions were fina-
lised across all sites by 30 April 2019. All follow-up assess-
ments were completed and data entered by 2 May 2019.
Qualitative interview recruitment commenced on 1 Sep-
tember 2017 and finished on 22 January 2019. Statistical
and qualitative analyses are currently ongoing. This paper
represents version 5 (17 July 2018) of the MAPS protocol.
All Principal Investigators, the REC and HTA were
informed of protocol modifications.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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